Cantor Fitzgerald analyst Rick Bienkowski reiterated an Overweight rating on Beam Therapeutics Inc (NASDAQ: BEAM).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE